RecruitingPhase 3NCT05623020

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS DARATUMUMAB + BORTEZOMIB + LENALIDOMIDE + DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

Sponsor

Pfizer

Enrollment

1,116 participants

Start Date

Nov 10, 2022

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in people with newly diagnosed multiple myeloma. There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination regimen. Part 2 of the study will evaluate the rate of minimal residual disease (MRD) negative CR and the progression free survival (PFS) of the combination of elranatamab, daratumumab, and lenalidomide compared with the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether a three-drug combination — elranatamab, daratumumab, and lenalidomide — works better than the standard two-drug treatment for people newly diagnosed with multiple myeloma (a cancer of the blood's plasma cells) who are not planning to receive a stem cell transplant. **You may be eligible if...** - You have been newly diagnosed with multiple myeloma and are not eligible for, or have chosen to delay, a stem cell transplant - You are 65 or older, or younger than 65 with health conditions that make transplant risky - You are generally able to carry out daily activities (not bedridden) - You are not pregnant and willing to use contraception **You may NOT be eligible if...** - You have smoldering myeloma, a different plasma cell disorder, or plasma cell leukemia - You have an active, uncontrolled infection (including HIV, hepatitis B or C, or COVID-19) - You have had another cancer in the past 3 years (with some exceptions for minor skin cancers) - You have received prior systemic treatment for myeloma (beyond a short course of steroids) - You received a live vaccine within the past 4 weeks Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGElranatamab

Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

DRUGDaratumumab

Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

DRUGLenalidomide

Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.

DRUGDexamethasone

Randomized

DRUGBortezomib

Randomized

Locations(89)

Pindara Private Hospital

Benowa, Queensland, Australia

St Vincent's Hospital Melbourne

Fitzroy, Victoria, Australia

Epworth Freemasons

Melbourne, Victoria, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Epworth Healthcare

Richmond, Victoria, Australia

Dr. Everett Chalmers Regional Hospital

Fredericton, New Brunswick, Canada

QEII Health Sciences Centre

Halifax, Nova Scotia, Canada

Nova Scotia Health Authority

Halifax, Nova Scotia, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Peking University Third Hospital

Beijing, Beijing Municipality, China

Fujian Medical University Union Hospital

Fuzhou, Fujian, China

Southern Medical University Nanfang Hospital

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China

Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China

Nanjing Drum Tower Hospital

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

The first hospital of jilin university

Changchun, Jilin, China

Tongji University - Shanghai Fourth People's Hospital

Shanghai, Shanghai Municipality, China

Institute of hematology&blood disease hospital

Tianjin, Tianjin Municipality, China

The first Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

The first Affiliated hospital of Wenzhou medical University

Wenzhou, Zhejiang, China

Fakultní nemocnice Brno Bohunice

Brno, Brno-město, Czechia

Fakultni nemocnice Olomouc

Olomouc, Czechia

Vseobecna fakultni nemocnice v Praze

Prague, Czechia

Institut Universitaire du Cancer Toulouse - Oncopole - CHU de TOULOUSE

Toulouse, Haute-garonne, France

Centre Hospitalier Universitaire de Poitiers

Poitiers, Vienne, France

Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu

Nantes, France

Universitaetsklinikum Tuebingen

Tübingen, Baden-Wurttemberg, Germany

Klinikum Chemnitz

Chemnitz, Germany

Evangelismos General Hospital of Athens

Athens, Attikí, Greece

Alexandra General Hospital of Athens

Athens, Attikí, Greece

"Theagenio" Cancer Hospital of Thessaloniki

Thessaloniki, Kentrikí Makedonía, Greece

Evangelismos General Hospital of Athens

Athens, Greece

University Hospital of Ioannina

Ioannina, Ípeiros, Greece

Rabin Medical Center

Petah Tikva, Central District, Israel

The Edmond and Lily Safra Children's Hospital; The Chaim Sheba Medical Center

Ramat Gan, Central District, Israel

Hadassah Medical Center

Jerusalem, Jerusalem, Israel

Soroka Medical Center

Beersheba, Southern District, Israel

Sourasky Medical Center

Tel Aviv, TELL ABĪB, Israel

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori- IRST S.r.l

Meldola (Fc), Emilia-Romagna, Italy

AUSL di Piacenza

Piacenza, Emilia-Romagna, Italy

Ospedale Santa Maria delle Croci

Ravenna, Emilia-Romagna, Italy

IRCCS Casa Sollievo della Sofferenza

San Giovanni Rotondo, FG, Italy

Cro-Irccs

Aviano, Friuli Venezia Giulia, Italy

Fondazione IRCCS San Gerardo dei Tintori

Monza, Lombardy, Italy

Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino

Turin, Piedmont, Italy

A.O.U. Policlinico Paolo Giaccone

Palermo, Sicily, Italy

Azienda Ospedaliero Universitaria Pisana

Pisa, Tuscany, Italy

Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

Bergamo, Italy

Istituto Europeo di Oncologia IRCCS

Milan, Italy

ASL PESCARA-Presidio Ospedaliero Pescara

Pescara, Italy

Azienda Sanitaria Locale di Pescara

Pescara, Italy

AOU Policlinico Umberto I

Roma, Italy

University of Fukui Hospital

Yoshida-gun, Fukui, Japan

Gunma University Hospital

Maebashi, Gunma, Japan

Iwate Medical University Hospital

Yahaba-cho, Iwate, Japan

Tohoku University Hospital

Sendai, Miyagi, Japan

Shizuoka Cancer Center

Nagaizumi-cho, Shizuoka, Japan

Japanese Red Cross Medical Center

Shibuya-ku, Tokyo, Japan

Kyushu University Hospital

Fukuoka, Japan

National Hospital Organization Okayama Medical Center

Okayama, Japan

Osaka Metropolitan University Hospital

Osaka, Japan

Yamagata University Hospital

Yamagata, Japan

Albert Schweitzer Ziekenhuis, locatie Dordwijk

Dordrecht, South Holland, Netherlands

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wroclaw, Lower Silesian Voivodeship, Poland

Uniwersyteckie Centrum Kliniczne

Gdansk, Pomeranian Voivodeship, Poland

Pratia Onkologia Katowice

Katowice, Silesian Voivodeship, Poland

Chonnam National University Hwasun Hospital

Hwasun-gun, Jeonranamdo, South Korea

Seoul National University Bundang Hospital

Seongnam, Kyǒnggi-do, South Korea

Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul], South Korea

The Catholic Univ. of Korea Seoul St. Mary's Hospital(Seoul St. Mary's Hospital)

Seoul, Seoul-teukbyeolsi [seoul], South Korea

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul, Seoul-teukbyeolsi [seoul], South Korea

CHUS - Hospital Clinico Universitario

Santiago de Compostela, A Coruña [LA Coruña], Spain

Institut Català d'Oncologia (ICO) - Badalona

Badalona, Barcelona [barcelona], Spain

Institut Català d'Oncologia - L'Hospitalet

L'Hospitalet Del Llobregat, Barcelona [barcelona], Spain

Hospital Clínic de Barcelona

Barcelona, Catalunya [cataluña], Spain

Institut Català d'Oncologia (ICO) - Girona

Girona, Girona [gerona], Spain

Clinica Universidad de Navarra

Madrid, Madrid, Comunidad de, Spain

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Doctor Peset

Valencia, València, Spain

Hospital San Pedro de Alcántara

Cáceres, Spain

Hospital La Princesa

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Kantonsspital Winterthur

Winterthur, Switzerland

China Medical University Hospital

Taichung, Taiwan

Taichung Veterans General Hospital

Taichung, Taiwan

National Taiwan University Hospital

Taipei, Taiwan

Chang Gung Medical Foundation-Linkou Branch

Taoyuan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05623020

Related Trials

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

NCT026826671 location

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations